Unknown

Dataset Information

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.


ABSTRACT:

Purpose

Salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT) is the standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL). Salvage regimens have never been compared; their efficacy in the rituximab era is unknown.

Patients and methods

Patients with CD20(+) DLBCL in first relapse or who were refractory after first-line therapy were randomly assigned to either rituximab, ifosfamide, etoposide, and carboplatin (R-ICE) or rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP). Responding patients received high-dose chemotherapy and ASCT.

Results

The median age of the 396 patients enrolled (R-ICE, n = 202; R-DHAP, n = 194) was 55 years. Similar response rates were observed after three cycles of R

SUBMITTER: Gisselbrecht C 

PROVIDER: S-EPMC3664033 | biostudies-literature | 2010 Sep

REPOSITORIES: biostudies-literature